权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

BLR&D Research Career Scientist Award Application

BLR

基本信息

批准号：
10047283
负责人：
Yabing Chen
金额：
--
依托单位：
BIRMINGHAM VA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-10-01 至 2021-09-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10047283
关键词：
Animal Model Antibodies Antibody Therapy Apoptosis Area Atherosclerosis Award Biology Blood Vessels Cancer Biology Cardiology Cardiovascular Diseases Cell Differentiation process Cell physiology Cells Cessation of life Clinical Trials Collaborations Complex Development Diabetes Mellitus Disease Drug resistance End stage renal failure Gene Expression Regulation Goals Health Health Care Costs Hyperglycemia Intervention Investigation Longevity Malignant Neoplasms Malignant neoplasm of pancreas Medical center Medicine Modeling Molecular Molecular Target Nephrology Oxidative Stress Pathogenesis Pathogenicity Pathology Patient Care Phenotype Physicians Poly(ADP-ribose) Polymerases Prevention strategy Publishing Quality of life Receptor Signaling Regulation Research Resistance Role Scientist Signal Pathway Signal Transduction Smooth Muscle Myocytes TNFRSF10B gene Therapeutic Tissues Translating Translational Research Up-Regulation Vascular Diseases Vascular Smooth Muscle Vascular calcification Veterans antibody immunotherapy arterial stiffness base bone calcification cancer cell cancer drug resistance cancer therapy career gene function improved insight interest knockout gene macrophage military veteran mouse model novel osteogenic pancreatic neoplasm programs receptor recruit refractory cancer stem cells therapeutic target therapy resistant transcription factor tumorigenesis

项目摘要

Project Summary/Abstract My major research interest is to understand molecular mechanisms of gene regulation and function in the pathogenesis of cancer and cardiovascular disease, two major health burdens for our Veterans. We seek to determine the fundamental molecular signals that regulate cellular function, and translate the findings in the pathogenesis of disease using animal models, so as to identify novel molecular targets and strategies for prevention and intervention of disease. Translational research on cancer pathogenesis and resistance to therapy. We have been focused on the death receptor signaling pathways in regulating apoptosis of cancer cells and their roles in cancer tumorigenesis and resistance to therapy. Our studies have demonstrated that modulating the Death- Inducing Signaling Complex (DISC) determines the downstream survival and apoptosis signals. Recently, we discovered a novel regulator, poly(ADP-ribose) polymerase 1 (PARP1), in the death receptor-5 DISC that contribute to the resistance of pancreatic cancer to therapy, a critical hurdle for effective cancer treatment. Based on this novel finding, our current VA merit review award (2014-2018) is to delineate the mechanisms underlying DISC-associated PARP1 in regulating pancreatic cancer resistance to antibody immunotherapy with a humanized anti-death receptor 5 antibody (TRA-8/CS1008). I will continue my long-term collaboration with VA physician scientist, Jay M McDonald, MD (Pathology, Birmingham VA) and the inventor of TRA-8/CS1008, Tong Zhou, MD (Medicine, UAB). As CS1008 therapy has been effective in clinical trials for some cancer but resistant in others including pancreatic tumors, the overarching goal for our investigations is to elucidate the molecular mechanisms and identify new compounds that sensitize pancreatic cancer to TRA-8-induced apoptosis, thus overriding drug resistance and leading to successful therapies. Differentiation and reprogramming of vascular smooth muscle cells in vascular disease. Phenotypic plasticity of vascular smooth muscle cells (VSMC) provides an excellent model to study the function of cell differentiation in health and disease. We are particularly interested in studying how VSMC become bone-like cells (vascular calcification). Using tissue-specific gene knockout mouse models, we have demonstrated an essential role of the osteogenic transcription factor Runx2 in regulating vascular calcification, a feature of atherosclerosis, diabetes and end stage renal disease. We have uncovered novel mechanisms underlying Runx2 upregulation in the vasculature by increased oxidative stress and hyperglycemia. We have also discovered a novel crosstalk between VSMC, macrophages and vascular stem cells in the development of atherosclerotic calcification. We have published a body of work demonstrating a critical integrative role of Runx2 upregulation in VSMC in promoting vascular pathology, which has been highly recognized and cited. Our overarching goals are to identify novel mechanisms that regulate pathogenesis of vascular calcification and identify therapeutic targets. We have brought together several physician scientists at the Birmingham VA including Drs. Paul Sanders and Anupam Agarwal (Nephrology) as well as Dr. Louis Dell'Italia (Cardiology and Associate Chief of Staff). Our collaborative studies have led to the development of a Program Project to investigate “Novel Regulators for Vascular Disease”, which have been supported by the VA (2012-2016). These investigations will not only elucidate the fundamental molecular mechanisms underlying the regulation of cancer drug resistance and pathogenesis of vascular disease, but also provide novel molecular insights facilitating further studies to translate these findings into therapeutic strategies for patient care, so as to improve the Veterans' health, life span and quality of life.

项目总结/文摘